Switching CGRP(r) MoAbs in migraine: what evidence?
William David Wells-GatnikPaolo MartellettiPublished in: Expert opinion on biological therapy (2024)
While data considering the potential efficacy of CGRP(r) switching continues to grow, our expert opinion supports the most recent European Headache Federation statement regarding CGRP(r) MoAb prescribing practices, concluding that there remains insufficient data to determine the efficacy of this intervention. As this topic is of significant clinical importance, we recommend a call-to-action to expand on current data considering the therapeutic options for patients that discontinue CGRP(r) MoAb therapy.
Keyphrases
- electronic health record
- primary care
- big data
- randomized controlled trial
- end stage renal disease
- newly diagnosed
- ejection fraction
- emergency department
- stem cells
- prognostic factors
- data analysis
- machine learning
- patient reported outcomes
- clinical practice
- mesenchymal stem cells
- risk assessment
- adverse drug
- drug induced